drugset / Trial / NCT00252343
Efficacy and Safety of SR58611A in Patients With a Generalized Anxiety Disorder
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the efficacy of a fixed dose of SR58611A (350mg q12) compared to placebo in patients with GeneralizedAnxiety Disorder (GAD) using escitalopram (10 mg qd) as positive control. To evaluate the tolerability and safety of SR58611A in patients with GAD.
Timeline
- Start
- 2005-09
- Primary completion
- 2007-02
- Completion
- 2007-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | amibegron | Small molecule | 350 mg | — |